Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jan 5:6:6.
doi: 10.21037/tgh.2020.04.03. eCollection 2021.

Pancreatic cancer and immune checkpoint inhibitors-still a long way to go

Jessica Bian  1 , Khaldoun Almhanna  2
Affiliations
Editorial

Pancreatic cancer and immune checkpoint inhibitors-still a long way to go

Jessica Bian et al. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tgh.2020.04.03). KA served as the unpaid Guest Editor of the series and has a consulting agreement with Merck. JB has no conflicts of interest to declare. The series “GI malignancies and Immunotherapy” was commissioned by the editorial office without any funding or sponsorship.

References

    1. Balli D, Rech AJ, Stanger BZ, et al. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Clin Cancer Res 2017;23:3129-38. 10.1158/1078-0432.CCR-16-2128 - DOI - PubMed
    1. Vonderheide RH, Bayne LJ. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 2013;25:200-5. 10.1016/j.coi.2013.01.006 - DOI - PMC - PubMed
    1. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006;95:1474-82. 10.1038/sj.bjc.6603437 - DOI - PMC - PubMed
    1. Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 2014;15:829-40. 10.1016/S1470-2045(14)70236-0 - DOI - PubMed
    1. NewLink Genetics announces results from phase 3 IMPRESS trial of algenpantucel-L for patients with resected pancreatic cancer. Ames, IA: NewLink Genetics, May 9, 2016.

Publication types